CLAIMS

1. The use of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-l-yl]-N-cyclopropyl-4-methyl-benzamide or a pharmaceutically acceptable derivative thereof in the manufacture of a medicament for the treatment of acute exacerbations of chronic obstructive pulmonary disease.

2. The use of claim 1, wherein the 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-l-yl]-N-cyclopropyl-4-methyl-benzamide or a pharmaceutically acceptable derivative thereof is in the form of a single dose.

3. The use according to claim 2, wherein the single dose comprises 50 to 100 mg of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-l-yl]-N-cyclopropyl-4-methylbenzamide or a pharmaceutically acceptable derivative thereof.

4. The use according to claim 2, wherein the single dose comprises 60 to 90 mg of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-l-yl]-N-cyclopropyl-4-methylbenzamide or a pharmaceutically acceptable derivative thereof.

5. The use according to claim 2, wherein the single dose comprises 75 mg of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-l-yl]-N-cyclopropyl-4-methylbenzamide or a pharmaceutically acceptable derivative thereof.

6. The use according to claim 2, wherein the single dose comprises 75 mg of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-l-yl]-N-cyclopropyl-4-methylbenzamide in its free form.

7. A pharmaceutical composition for oral administration that contains 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-l-yl]-N-cyclopropyl-4-methylbenzamide or a pharmaceutically acceptable derivative thereof.

8. A pharmaceutical composition according to claim 7, that contains 50 to 100 mg of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-l-yl]-N-cyclopropyl-4-methylbenzamide or a pharmaceutically acceptable derivative thereof.

9. A pharmaceutical composition according to claim 8, that contains 60 to 90 mg of 3- [5-amino-4-(3-cyanobenzoyl)-pyrazol-l-yl]-N-cyclopropyl-4-methylbenzamide or a pharmaceutically acceptable derivative thereof.

10. A pharmaceutical composition according to claim 9, that contains 75 mg of 3-[5- amino-4-(3-cyanobenzoyl)-pyrazol-l-yl]-N-cyclopropyl-4-methylbenzamide or a pharmaceutically acceptable derivative thereof.

11. A pharmaceutical composition according to claim 10, that contains 75 mg of 3-[5- amino-4-(3-cyanobenzoyl)-pyrazol-l-yl]-N-cyclopropyl-4-methylbenzamide in its free form.

12. A pharmaceutical composition according to claim 7, in the form of a tablet.

13. A pharmaceutical composition according to claim 11, in the form of a tablet.

CLAIMS

1. The use of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-l-yl]-N-cyclopropyl-4-methylbenzamide or a pharmaceutically acceptable salt, hydrate and solvate thereof in the manufacture of a medicament for the treatment of acute exacerbations of chronic obstructive pulmonary disease.

2. The use of claim 1, wherein the 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-l-yl]-N-cyclopropyl-4-methyl-benzamide or a pharmaceutically acceptable salt, hydrate and solvate thereof is in the form of a single dose.

3. The use according to claim 2, wherein the single dose comprises 50 to 100 mg of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-l-yl]-N-cyclopropyl-4-methylbenzamide or a pharmaceutically acceptable salt, hydrate and solvate thereof.

4. The use according to claim 2, wherein the single dose comprises 60 to 90 mg of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-l-yl]-N-cyclopropyl-4-methylbenzamide or a pharmaceutically acceptable salt, hydrate and solvate thereof.

5. The use according to claim 2, wherein the single dose comprises 75 mg of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-l-yl]-N-cyclopropyl-4-methylbenzamide or a pharmaceutically acceptable salt, hydrate and solvate thereof.

6. The use according to claim 2, wherein the single dose comprises 75 mg of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-l-yl]-N-cyclopropyl-4-methylbenzamide in its free form.

7. A pharmaceutical composition for use in the treatment of acute exacerbations of chronic obstructive pulmonary disease that contains 3-[5-amino-4-(3- cyanobenzoyl)-pyrazol-l-yl]-N-cyclopropyl-4-methylbenzamide or a pharmaceutically acceptable salt, hydrate and solvate thereof wherein the composition is for oral administration.

8. The pharmaceutical composition according to claim 7, wherein the composition contains 50 to 100 mg of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-l-yl]-N-cyclopropyl-4-methylbenzamide or a pharmaceutically acceptable salt, hydrate and solvate thereof.

9. The pharmaceutical composition according to claim 8, wherein the composition contains 60 to 90 mg of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-l-yl]-N-cyclopropyl-4-methylbenzamide or a pharmaceutically acceptable salt, hydrate and solvate thereof.

10. The pharmaceutical composition according to claim 9, wherein the composition contains 75 mg of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-l-yl]-N-cyclopropyl-4-methyl-benzamide or a pharmaceutically acceptable salt, hydrate and solvate thereof.

11. The pharmaceutical composition according to claim 10, wherein the composition contains 75 mg of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-l-yl]-N-cyclopropyl-4-methyl-benzamide in its free form.

12. The pharmaceutical composition according to claim 7, in the form of a tablet.

13. The pharmaceutical composition according to claim 11, in the form of a tablet.